← ANALYST RATINGS · TIPRANKS
Insulet (PODD): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy7 Hold0 Sell
Ratings of 13 analysts in the last 3 months · top analysts only12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $163, the highest $190, the lowest $143. The average is +15.3% from the last price of $141.
Analyst ratings 29
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $275 → $190−30.9% | Buy | +34.7% | Reiterated | 12.10.26on TipRanks 08:35 | +3.4%next day −1.2% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $145 → $143−1.4% | Hold | +1.3% | Assigned | 12.10.26on TipRanks 07:35 | +3.4%next day −1.2% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $150 | Hold | +6.3% | Initiated | 07.10.26on TipRanks 03:55 | 0.0%next day +0.5% · 5 days +0.7% | ↗ |
| Name not given | — | $160 | Buy | +13.4% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | +0.1%next day −0.1% · 5 days +1.5% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | — | Hold | — | Reiterated | 30.09.26on TipRanks 06:55 | −1.6%next day +0.1% · 5 days +1.1% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $152 → $154+1.3% | Hold | +9.1% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $148 → $152+2.7% | Hold | +7.7% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $152 → $153+0.7% | Hold | +8.4% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $148 → $152+2.7% | Hold | +7.7% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $154 → $157+1.9% | Buy | +11.3% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $157 → $159+1.3% | Buy | +12.7% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $150 | Hold | +6.3% | Assigned | 12.08.26on TipRanks 08:00 | 0.0%next day +0.3% · 5 days +4.9% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $248 → $175−29.4% | Buy | +24.0% | Reiterated | 06.08.26on TipRanks 09:35 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Kieran Ryan | Deutsche Bank | $190 → $180−5.3% | Buy | +27.6% | Reiterated | 06.08.26on TipRanks 09:15 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $250 → $185−26.0% | Buy | +31.1% | Reiterated | 06.08.26on TipRanks 08:40 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $180 | Buy | +27.6% | Reiterated | 06.08.26on TipRanks 08:25 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | $200 → $175−12.5% | Buy | +24.0% | Reiterated | 06.08.26on TipRanks 07:55 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | $225 → $180−20.0% | Buy | +27.6% | Assigned | 06.08.26on TipRanks 07:55 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $145 | Hold | +2.8% | Downgrade | 06.08.26on TipRanks 07:35 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $249 → $179−28.1% | Buy | +26.9% | Reiterated | 06.08.26on TipRanks 07:10 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | — | Hold | — | Downgrade | 06.08.26on TipRanks 05:55 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $210 → $153−27.1% | Hold | +8.4% | Downgrade | 06.08.26on TipRanks Aug 5 16:40 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Mathew Blackman★★★★★★★★★★#2177 · hits 49% · avg +9.2% | TD Cowen | $294 → $144−51.0% | Hold | +2.1% | Assigned | 06.08.26on TipRanks Aug 5 16:30 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Name not given | — | $245 → $160−34.7% | Buy | +13.4% | Reiterated | 05.08.26on TipRanks Aug 6 07:00 | −19.9%next day +4.7% · 5 days +8.5% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $275 → $152−44.7% | Hold | +7.7% | Downgrade | 05.08.26on TipRanks Aug 6 05:00 | −19.9%next day +4.7% · 5 days +8.5% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $255 → $144−43.5% | Hold | +2.1% | Downgrade | 05.08.26on TipRanks 18:20 | +4.7%next day +0.7% · 5 days +3.9% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Reiterated | 05.08.26on TipRanks 15:45 | −19.9%next day +4.7% · 5 days +8.5% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | — | Hold | — | Downgrade | 05.08.26on TipRanks 14:10 | −19.9%next day +4.7% · 5 days +8.5% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $208 | Buy | +47.4% | Reiterated | 23.06.26on TipRanks 07:09 | +5.0%next day +3.5% · 5 days +4.0% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $210 | Buy | +48.8% | Reiterated | 15.06.26on TipRanks 06:55 | −2.8%next day +0.3% · 5 days −0.3% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $263 → $216−17.9% | Buy | +53.1% | Reiterated | 08.06.26on TipRanks 15:30 | −1.3%next day +5.6% · 5 days −4.3% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $198 | Sell | +40.3% | Reiterated | 28.05.26on TipRanks 05:05 | −2.9%next day +1.4% · 5 days +2.3% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $237 → $205−13.5% | Buy | +45.3% | Reiterated | 27.05.26on TipRanks 07:35 | −5.0%next day −2.9% · 5 days −2.4% | ↗ |
| Issie Kirby★★★★★★★★★★#9228 · hits 27% · avg −2.0% | Rothschild & Co Redburn | $380 → $220−42.1% | Hold | +55.9% | Downgrade | 24.04.26on TipRanks 05:11 | −2.2%next day −0.8% · 5 days −8.6% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $400 | Buy | +183.5% | Reiterated | 19.02.26on TipRanks 08:50 | −3.2%next day −3.6% · 5 days +0.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Insulet
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $164 at a price of $130 (+26.0%); now: $165 at $141 (+16.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 1 | 0 | 0 |
| Buy | 6 | 9 | 10 | 11 | 8 | 6 |
| Hold | 1 | 1 | 1 | 6 | 6 | 8 |
| Sell | 2 | 2 | 2 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.59 (from $1.53 to $1.66). Last quarter: $1.66.
Sales
Next quarter’s sales estimate — $833M (from $826M to $838M). Last quarter: $802M.
Best top-analyst consensus in the sector · Healthcare
About Insulet
- CEO: Ashley McEvoy
- Employees: 5,400
- 100 Nagog Park, Acton, MA, 01720, US
- www.insulet.com
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Data from the stock’s TipRanks forecast page, read 17 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗